Investing in pharmaceutical companies should consider their pipeline strength over current profits, as temporary sales of blockbuster drugs can impact earnings. Pfizer and AbbVie exemplify this, with Pfizer’s Covid vaccine sales boosting profits temporarily, while AbbVie’s Humira faced generic competition but had new drugs in the pipeline. Companies like Novo Nordisk and Eli Lilly are focusing on weight-loss drugs with additional benefits, while AstraZeneca and Merck are prominent in the cancer drug market. Assessing investment potential, Novo and AstraZeneca offer lower risk, Eli Lilly and AbbVie provide reasonable risk/reward profiles, and Merck poses higher risk due to dependency on Keytruda.
Full Article
Social Security: This Hidden Threat Could Cost the Average Retiree $4,440 Per Year
Social Security is vital for about 16 million seniors, preventing poverty annually, but faces challenges such as potential benefit cuts and a significant loss of buying power that could cost retirees over $4,000 each year. This uncertainty raises concerns about the program's future effectiveness as a financial lifeline for many Americans. Explain It To Me Like I'm 5: Social Security helps many older people in America have enough money to live, but there are worries...
Read more